Linked Life Data

12026045

Source:http://linkedlifedata.com/resource/pubmed/id/12026045

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2002-5-23
pubmed:abstractText
Anorexia is a common problem in advanced cancer. Low-dose megestrol acetate, a semi-synthetic progesterone, given twice daily, is an effective appetite stimulant in advanced cancer patients. There was an excellent correlation between patient satisfaction and the primary response criteria (appetite improvement). Given cost, side-effect profile, ease of administration, and efficacy, 80 mg twice daily after meals is an appropriate starting dose of megestrol acetate for anorexia in advanced cancer. If this is not effective, considerable dose escalation is possible.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
N
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1049-9091
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
206-10
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:articleTitle
A phase II study of low-dose megestrol acetate using twice-daily dosing for anorexia in nonhormonally dependent cancer.
pubmed:affiliation
Taussig Cancer Center, Cleveland Clinic Foundation, Ohio, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase II